Abstracts tagged "Cholesterol"

Abstract Number: 766 • 2013 ACR/ARHP Annual Meeting
Cholesterol Accumulation By Synovial Lining Macrophages Results In Ectopic Bone Formation During Experimental Osteoarthritis
Wouter de Munter¹, Arjen B. Blom¹, Monique M. Helsen¹, Birgitte Walgreen¹, Peter M. van Der Kraan¹, Leo A. Joosten², Wim B. van den Berg³ and Peter L. van Lent⁴, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ⁴Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial macrophages have previously shown to play a significant role in the etiopathology of experimental collagenase-induced osteoarthritis (OA). In addition to production of pro-inflammatory…
Abstract Number: 470 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: Relationship Between Inflammation Suppression and Changes In Cholesterol Levels
Christina Charles-Schoeman¹, Steven P. Weinstein², Janet van Adelsberg³, Tanya Momtahen⁴, Richard Wu⁵, Neil Graham⁶ and Stefano Fiore⁷, ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα) which is currently being evaluated for…
Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Julio C. B. Moraes¹, Carla G.S. Saad¹, Ana Cristina Ribeiro², Claudia G Schainberg³, Celio R. Gonçalves², Percival D Sampaio-Barros¹ and Eloisa Bonfá², ¹Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…
Abstract Number: 52 • 2013 ACR/ARHP Annual Meeting
Altered Lipid Metabolism In Osteoarthritis With Subsequent Proinflammatory Properties Of Apolipoprotein A-I
Dominique de Seny¹, Gaël Cobraiville², Edith Charlier³, Sophie Neuville², Laurence Lutteri⁴, Denis Malaise⁵, Olivier Malaise³, Jean-Paul Chapelle⁴, Biserka Relic¹ and Michel G. Malaise¹, ¹Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ²GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ⁴Medical Chemistry - CHU Liège, Liège, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: Osteoarthritis (OA) is associated with a local inflammatory process. It is now considered as a metabolic syndrome rather than due to aging or mechanical…
Abstract Number: 2515 • 2012 ACR/ARHP Annual Meeting
Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions
Wouter de Munter, Birgitte Walgreen, Monique M. Helsen, Annet W. Sloëtjes, Wim B. van den Berg and Peter L.E.M. van Lent, Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Synovial macrophages are involved in osteophyte formation during experimental collagenase-induced osteoarthritis (OA). Accumulated LDL can be oxidized in an inflammatory environment such as OA…
Abstract Number: 2157 • 2012 ACR/ARHP Annual Meeting
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Allison B. Reiss¹, Iryna Voloshyna¹, Ofek Hai¹, Michael J. Littlefield¹, Elise Belilos², Kristina B. Belostocki², Lois A. Bonetti³, Gary C. Rosenblum² and Steven E. Carsons⁴, ¹Medicine, Winthrop University Hospital, Mineola, NY, ²Rheumatology, Winthrop University Hospital, Mineola, NY, ³Rheum & Immun, Winthrop University Hospital, Mineola, NY, ⁴Div of Rheumatology, Winthrop University Hospital, Mineola, NY
Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic…
Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Roy Fleischmann², Jean Davignon³, Howard Schwartz⁴, Scott Turner⁵, Carine Beysen⁵, Mark Milad⁶, Zheng Luo⁷, John Bradley⁸, Irina Kaplan⁸, Richard Riese⁷, Andrea Zuckerman⁷ and Iain B. McInnes⁹, ¹University of California, Los Angeles, CA, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Montreal, Montreal, Canada, ⁴Miami Research Associates, Miami, FL, ⁵KineMed Inc., Emeryville, CA, ⁶Milad Pharmaceutical Consulting LLC, Plymouth, MI, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc, Groton, CT, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].